Regarding lipid metabolism, mTOR blocks not only FFA formation and DNL, the source of abnormal liver lipid metabolism, but also the transcription of INSIG, the key gene determining SREBP production, thus inhibiting the development of NAFLD by altering the metabolism. Here, MTOR is linked to metabolic dysfunction-associated steatotic liver disease.